Medicare

Annual Medicare Expense for Anti-VEGF Injections Tops $4 Billion, Study Finds

A significant rise ($1.5 billion more per year) can be attributed to greater uptake of aflibercept by retina specialists. Regional differences reflect local variation in disease burden.
02/21/2024

Age-related Eye Diseases Higher in Prevalence, Incidence Over 15 Years

While the trends reported represent small changes, due to the size of the US Medicare beneficiary population these differences equate to a large number of individuals and considerable economic cost.
07/26/2023

Lack of Eye Care Access in US Reflects Socioeconomic Trends

Patients with Medicare in areas that were rural, had lower household incomes or higher unemployment rates did not make significant use of available services.
05/30/2023

Upcoming Events

November 6, 2024

Showcasing Inflammation and IOP Control
Location: Prime 47
Presenters: Marc Bloomenstein, OD, and Nora Lee Cothran, OD
Time: 7:00pm CT

Sponsored by Bausch + Lomb

Register here

November 13, 2024

Rethinking Dry Eye Disease: A Contemporary Approach to a Complex Condition
Location: Virtual
Presenters: Harry Boparai, OD, and Doug Katsev, MD
Webinar: 7:00pm PT

Sponsored by Bausch + Lomb

Register here

November 13, 2024

The 3 I's of Geographic Atrophy: Imaging, Identification, and Intervention
Location: Virtual
Presenters: Jordana Fein, MD, and Julie Rodman, OD, MS, 
Webinar: 9:30pm ET


Sponsored by Apellis

Register here